From Stigma to Pharmacology
Cannabidiol (CBD) is one of over 100 phytocannabinoids in Cannabis sativa. Unlike tetrahydrocannabinol (THC), CBD has no psychoactive properties and does not cause intoxication. The WHO concluded in its 2018 report that CBD "exhibits no effects indicative of any abuse or dependence potential."
Epidiolex — pure CBD — became the first cannabinoid-derived medication approved by the FDA (2018) for treating rare forms of epilepsy (Lennox-Gastaut and Dravet syndromes). This approval legitimized CBD as a pharmacologically active substance with proven clinical efficacy.
The Endocannabinoid System (ECS)
The endocannabinoid system is a fundamental regulatory system discovered in the 1990s. It comprises three components: endocannabinoids (anandamide and 2-AG), cannabinoid receptors (CB1 and CB2), and synthesis/degradation enzymes (FAAH, MAGL).
CB1 receptors are predominantly in the central nervous system (especially hippocampus, basal ganglia, cerebellum, neocortex). They regulate neurotransmission, pain, mood, appetite, and memory.
CB2 receptors are predominantly in immune cells (microglia, macrophages, spleen). They regulate inflammation, immune response, and neuroinflammation.
CBD does not directly bind CB1/CB2 receptors (unlike THC). Instead, it acts as a negative allosteric modulator of CB1 and indirectly raises endocannabinoid levels by inhibiting FAAH (the enzyme that degrades anandamide). Additionally, CBD interacts with serotonin 5-HT1A receptors, TRPV1 receptors (pain modulation), and PPARgamma receptors (anti-inflammatory).
CBD for Chronic Pain
### Pain Mechanisms
CBD modulates the pain signal at multiple levels: 1) TRPV1 receptor activation (pain neuron desensitization), 2) increased anandamide via FAAH inhibition, 3) glycine receptor alpha-3 modulation (inflammatory pain suppression), 4) inhibition of pro-inflammatory cytokine release (TNF-alpha, IL-1beta, IL-6).
### Clinical Evidence
Argueta et al. (Journal of Cannabis Research, 2020) reviewed 25 RCTs showing cannabinoids (including CBD-dominant preparations) demonstrate moderate analgesic effects for neuropathic and chronic pain. Best results were seen in neuropathic pain and MS-related spasticity.
Nabiximols (Sativex) — a 1:1 CBD:THC combination — is approved in 25 countries for MS spasticity. CBD monotherapy shows more modest but statistically significant results in fibromyalgia and arthritis.
CBD for Anxiety
### Molecular Mechanisms
CBD anxiolytic effects work through: 1) serotonin 5-HT1A receptor agonism (similar to buspirone), 2) GABAergic neurotransmission modulation, 3) reduced amygdala activity (fear center), 4) hippocampal neurogenesis via increased BDNF.
### Key Studies
Bergamaschi et al. (Neuropsychopharmacology, 2011): single CBD 600 mg dose significantly reduced anxiety, cognitive impairment, and discomfort during public speaking in patients with social phobia. Effect comparable to benzodiazepines but without sedation.
Zuardi et al. (Journal of Psychopharmacology, 2017): CBD 300 mg reduced anxiety in a simulated public speaking test in healthy volunteers. Notably, 150 mg and 600 mg were less effective — a typical inverted U-shaped dose-response curve.
Shannon et al. (The Permanente Journal, 2019): CBD 25-75 mg/day for 3 months reduced anxiety in 79.2% and improved sleep in 66.7% of patients. Anxiety scores remained improved throughout the observation period.
CBD for Neuroinflammation
Neuroinflammation — chronic activation of microglia and astrocytes — is recognized as a key mechanism in neurodegenerative diseases (Alzheimer's, Parkinson's), depression, and chronic pain.
CBD modulates neuroinflammation through: inhibiting microglial activation (M1 to M2 phenotype switching), reducing pro-inflammatory cytokine production, activating PPARgamma receptors, and enhancing antioxidant systems (increasing glutathione).
Fernandez-Ruiz et al. (British Journal of Clinical Pharmacology, 2013) review: CBD demonstrates neuroprotective potential in models of Alzheimer's, Parkinson's, multiple sclerosis, ALS, and Huntington's disease.
Practical Guide
### Forms and Bioavailability
### Dosing
Principle: "start low, go slow" - Starting dose: 10-15 mg/day - Titration: increase by 5 mg every 3-5 days - Standard anxiety dose: 25-50 mg/day - Standard chronic pain dose: 50-150 mg/day - High doses (epilepsy, supervised): 200-600 mg/day
### Choosing Quality CBD
1. Full-spectrum vs Broad-spectrum vs Isolate: Full-spectrum contains all cannabinoids (including trace THC <0.3%), providing the "entourage effect." Broad-spectrum is THC-free. Isolate is pure CBD. 2. CO2 extraction: supercritical CO2 extraction is the gold standard for purity. 3. Certificate of Analysis (COA): from independent lab. Check: CBD content, THC (<0.3%), heavy metals, pesticides, mycotoxins. 4. Source: hemp grown in the EU or USA with GMP certification.
Drug Interactions
CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19), slowing the metabolism of several medications: - Anticoagulants (warfarin) — increased INR - Benzodiazepines (diazepam, midazolam) — enhanced sedation - Anticonvulsants (clobazam) — elevated N-desmethylclobazam levels - Statins — increased concentration - Immunosuppressants (cyclosporine, tacrolimus) — elevated levels
Legal Status
CBD legal status varies significantly by country. In the EU, CBD products from industrial hemp (<0.3% THC) are legal in most countries. In the USA, federally legal after the Farm Bill (2018). In Thailand, legalized since 2022. Always check local regulations.
Frequently Asked Questions
Does CBD cause intoxication? No. CBD has no psychoactive properties. THC is the psychoactive component. Full-spectrum CBD contains <0.3% THC — insufficient for any psychoactive effect.
Will CBD show on a drug test? Isolate and Broad-spectrum should not. Full-spectrum at high doses could theoretically cause a false positive for THC. For regular testing, Broad-spectrum is recommended.
Is CBD safe long-term? Safety data extends to approximately 2 years. Main side effects: diarrhea, fatigue, appetite changes. At doses >300 mg/day, liver enzyme monitoring is advised.
What dose should I start with for anxiety? 10-15 mg sublingually in the evening. Increase by 5 mg every 3-5 days to 25-50 mg/day. Effect typically appears within 1-2 weeks.
*This article is for educational purposes only. CBD may interact with medications. Consult your physician before starting supplementation.*
